Gandolfo has more than 30 years of experience in executive and senior management positions with high growth public and private companies, primarily in the medical devices and life sciences sectors.
He has assisted in raising approximately USD 500m in capital through public market transactions and private investors, venture capitalists and debt transactions.
Prior to joining Eyenovia, Gandolfo spent more than seven years at Xtant Medical Holdings, Inc., where he served as CFO. He has also served as the CFO at Progenitor Cell Therapy LLC, Power Medical Interventions, Inc., and Bioject, Inc.
Gandolfo is a graduate of Rutgers University and started his professional career at Price Waterhouse.
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics.
The company's pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business